Arasid

Arasid

cytarabine

Manufacturer:

Intas

Distributor:

Accord Healthcare
Concise Prescribing Info
Contents
Cytarabine
Indications/Uses
Alone or in combination w/ other chemotherapeutic agents for induction of leukaemia remission, particularly for acute myeloid leukaemia in adult & childn. Remission induction in acute lymphocytic leukaemia, chronic myeloid leukaemia & erythroleukaemia; treatment & maintenance therapy of meningeal leukaemia & neoplasms.
Dosage/Direction for Use
Monotherapy in induction remission & maintenance in adult & childn w/ acute myelocytic leukaemia, acute lymphocytic leukaemia 200 mg/m2 daily by continuous IV infusion over 24 hr for 5 days, repeat course approx every 2 wk. Intrathecal use in meningeal leukaemia 30 mg/m2 every 4 days until CSF findings were normal, followed by 1 additional treatment. Dose range: 5-75 mg/m2 once daily for 4 days to once every 4 days.
Contraindications
Hypersensitivity. Preexisting drug-induced bone marrow suppression. Management of non-malignant disease, except for immunosuppression.
Special Precautions
Not for intrathecal use. Frequently perform leucocyte & platelet counts. CNS, GI & pulmonary toxicity. Monitor serum uric acid regularly. Perform periodic determinations of renal & hepatic functions & bone marrow. Hepatic impairment. Not to be used during pregnancy especially in 1st trimester. Not to be used in lactation. Infant.
Adverse Reactions
Haematological toxicity, myelosuppression manifested by megaloblastosis, reticulocytopenia thrombocytopenia & anaemia; nausea, vomiting, diarrhoea, anorexia, oral & anal inflammation or ulceration; fever, rash, alopecia, skin ulceration, conjunctivitis, chest pain, urinary retention, dizziness, neuritis, neurotoxicity or neural toxicity & pain, cellulitis & thrombophlebitis (ie, irritation or sepsis) at inj site; renal & hepatic dysfunction, jaundice; freckling, skin, mucosal bleeding & joint pain; hyperuricaemia.
Drug Interactions
Substantially reduced digoxin GI absorption. Antagonized activity of gentamicin against Klebsiella pneumoniae. Antagonized activity of flucytosine.
ATC Classification
L01BC01 - cytarabine ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer.
Presentation/Packing
Form
Arasid soln for inj 100 mg/mL
Packing/Price
1 mL x 1's;10 mL x 1's;5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in